University of Texas at Arlington

MavMatrix

Doctor of Nursing Practice (DNP) Scholarly Projects

Department of Graduate Nursing

Spring 2024

Improving Heart Health in African Americans Using a Cardiovascular Disease Bundle

Loretta N. Bennam University of Texas at Arlington

Follow this and additional works at: https://mavmatrix.uta.edu/nursing_dnpprojects

Part of the Family Practice Nursing Commons

Recommended Citation

Bennam, Loretta N., "Improving Heart Health in African Americans Using a Cardiovascular Disease Bundle" (2024). *Doctor of Nursing Practice (DNP) Scholarly Projects*. 1. https://mavmatrix.uta.edu/nursing_dnpprojects/1

This Thesis is brought to you for free and open access by the Department of Graduate Nursing at MavMatrix. It has been accepted for inclusion in Doctor of Nursing Practice (DNP) Scholarly Projects by an authorized administrator of MavMatrix. For more information, please contact leah.mccurdy@uta.edu, erica.rousseau@uta.edu, vanessa.garrett@uta.edu.

Improving Heart Health in African Americans Using a Cardiovascular Disease Bundle

Loretta N. Bennam, APRN, FNP-C

College of Nursing and Health Innovation, The University of Texas Arlington

NURS 6621

March 24, 2024

Acknowledgements:

Faculty Project Adviser: Dr. Tiffany Trent Statistician: Dr. Yungfei Kao

Improving Heart Health in African Americans Using a Cardiovascular Disease Bundle Abstract

Cardiovascular disease (CVD) is a significant cause of mortality in the United States of America. Risk factors include abnormal low-density lipoprotein (LDL) cholesterol, physical inactivity, and unhealthy diets. African American (AA) adults have higher mortality rates from CVD than other demographics. In Houston, Texas, age-adjusted death rates for CVD per 100,000 population by race in AAs were 111, 85.0 in Whites, 62.9 in Hispanics, and 49.5 in Asians. This project evaluated the impact of using a CVD bundle over an eight-week period on cholesterol medication adherence, physical activity, and heart disease knowledge and was titled Improving Heart Health in African Americans Using a Cardiovascular Disease Bundle. Forty participants were recruited; 19 completed the project. Medication adherence, weight, LDL, physical activity, and heart disease knowledge measures were taken at baseline and eight weeks. The Medication Adherence Reporting Scale (MARS-5) measured adherence to cholesterol medication. Physical activity levels were measured using the Rapid Assessment of Physical Activity (RAPA) questionnaire, and heart disease knowledge was assessed using a Heart Disease Education Survey. The mean age of participants was 53 years; 58% were female. A paired samples t-test revealed a significant difference between all data pairs: MARS-5, t (18) = -8.024, p<0.001; RAPA-1, t (18) = 7.435, p<0.00; RAPA-2 t (18) =13.568, p<0.001; weight t (18) = 2.105, p<0.025; LDL t (18) =5.079, p<0.001; total heart education scores, t (18) = -18.000, p<0.001. This indicates that the CVD bundle effectively improved cholesterol medication adherence, increased physical activity, and increased knowledge of heart disease at eight weeks, providing a basis for long-term evaluation of the CVD bundle.

Introduction

Cardiovascular disease (CVD) or heart disease is a significant cause of mortality in developed countries like the United States of America (USA) and worldwide. 17.5 million people die annually from CVD (World Health Organization, 2022a). According to the Centers for Disease Control and Prevention (CDC), CVD kills 695,000 people annually in the USA, an average of one person every five seconds (CDC, 2020). In addition, African Americans (AA) are at a higher risk for heart disease than other ethnic groups, with AA adults having a higher likelihood of suffering from heart attacks, high blood pressure, and stroke-related deaths than Caucasians (CDC, 2023).

Three main risk factors for CVD are elevated low-density lipoprotein (LDL), obesity, and physical inactivity; other risk factors are unhealthy diet, diabetes mellitus, excessive alcohol use, high blood pressure, and smoking (CDC, 2020). Healthcare interventions to decrease CVD risk factors are essential to promote public health and reduce disease burden.

High cholesterol contributes to CVD by causing a buildup of plaque in the arteries, which can cause heart attack or stroke. LDL is known as bad cholesterol, and normal blood levels of LDL should stay at approximately 100mg/dl (CDC, 2019). Obesity is defined as a body mass index (BMI) of 30 kg/m² and above (Mayo Clinic, 2021), with 33.9 percent of the USA population being obese (America's Health Rankings, 2022). Consumption of unhealthy foods, sugars, and processed foods, combined with physical inactivity, contributes to obesity. Per the World Health Organization (WHOa, 2022), less than 30 minutes of moderate-intensity physical exercise for most days of the week constitutes physical inactivity and results in a 20-30 percent higher risk of all-cause mortality (WHOb, 2022). These three risk factors contribute significantly to the development of CVD.

Background

As previously stated, 695,000 people died from heart disease in the USA in 2021 (CDC, 2022). Of this number, the highest percentage of deaths per race at 22.6 percent mortality was of Blacks and non-Hispanics, followed by Asians at 18.6 percent (CDC, 2022). Due to these alarming statistics, when AA patients are diagnosed with high cholesterol, especially as young adults, it is vital to prescribe medication treatment if diet and exercise alone are ineffective.

According to Nanna et al. (2018), AAs are less likely to be treated with statin medications than Caucasians (71% vs. 75%, p=0.02). This data indicates a gap in CVD treatment in AAs, in which poor management of risk factors like high LDL contributes significantly to heart disease prevalence and mortality. In addition, AAs were 20 percent less likely to engage in active physical activity than non-Hispanic Whites in 2018 and 1.3 times more likely to be obese than Caucasians (US Department of Health and Human Services, 2019), placing them at a higher risk for developing CVD. The root of these differences is often challenging to explain and may be linked to genetics or healthcare disparities in access to healthcare, unemployment, and food insecurity. Subsequently, timely and efficient management of CVD risk factors like high LDL, physical inactivity, and obesity is crucial to mitigate the gap in CVD management for AA patients.

The National Vital Statistics System (NVSS) mortality data for the Black non-Hispanic population puts the crude death rate per 100,000 at 213.9 from heart disease and 51.4 from stroke (CDC, 2021; National Center for Health Statistics, 2021). In addition, the National Vital Statistics' 2019 leading causes of death data indicated higher death rates from heart disease in AAs compared to Caucasians beginning around the age of 35, with significant differences evident in age ranges 35 to 64 (Heron et al., 2021). Refer to the heart disease mortality rates per age group for a summary of information on heart disease for Whites and Blacks (Appendix A). Though there is a national decrease in disparities in cardiovascular (CV) mortality between Whites and Blacks, CV mortality rates are still 21 percent higher in Blacks than Whites (Dyke, 2018). According to USA Health Rankings (2022), heart disease was the leading cause of death per 100,000 in Texas in 2021, with a mortality rate of 180.7 compared to a national average mortality rate of 173.78. AAs tend to have higher LDL levels than Caucasians, with 32.4 percent of AA men having high LDL levels compared to 31.7 percent of Caucasian men (Lee-Frye, 2022). High LDL levels in Texas for AAs are 35.8 percent, higher than the national rate of 35.7 percent (America's Health Rankings, 2022). Although screening and treatment for heart disease have improved, heart disease mortality is still higher in the AA demographic. Per the CDC, decreases in CV mortality rates are less in the AA population compared to other races (Dyke, 2018). This data supports the gap in the treatment of heart disease in the AA demographic at the state level.

Locally, Houston State of Health (2023) reports that the age-adjusted death rate for coronary heart disease per 100,000 population by race in Blacks was 111, 85.0 in Whites, 62.9 in Hispanics, and 49.5 in Asians/Pacific. This indicates higher mortality rates from CVD in AAs in Houston, Texas, compared to other races. CVD remains the leading cause of mortality in Houston at 174.6 per 100,000 people (Houston Health Department, 2019). High cholesterol prevalence in 2019 in Houston was 37.3 percent, with 33.3 percent prevalence for AAs and 33.9 percent for Caucasians (Houston State of Health, 2023). Even though AAs in Houston have slightly lower rates of high cholesterol compared to Caucasians, their mortality rate from CVD is higher than that of Caucasians, further supporting the gap in care for this demographic.

Review of Literature

Selected databases for this review were from three disciplines: nursing, medicine, and education. This included the Cumulative Index to Nursing and Allied Health Literature (CINAHL), Joanna Briggs Institute (JBI), the Cochrane Library for Nursing, PubMed for Medicine, and the Education Resources Information Center (ERIC) for Education. Key terms used included "African American", "hyperlipidemia", "treatment", "barriers", "intervention", "primary care", and "education". Other search terms included "compliance", "medication", "diet and exercise", "lifestyle change", and "cardiovascular". The Boolean operators "and" and "or" were used individually or in combination with the keywords to search the sections of the PICOT(S).

The initial search for the nursing discipline resulted in over 111 articles, while that for the medicine discipline yielded over 29 articles, and the education search yielded 24 articles. Inclusion and exclusion criteria were utilized to narrow the articles further and remove duplicate reports. The inclusion criteria included articles published in English in the last five years, peer-reviewed articles on adults over 18 years, and human studies. Exclusion criteria included articles not written in English and non-human studies. Ten pieces were retained. Refer to the evidence table in Appendix B for a summary of the evidence supporting the PICOTS.

Synthesis of Evidence

The literature review aims to identify studies focusing on evidence-based interventions that improve compliance with treatment in AA adults with cardiovascular disease. Maintaining healthy LDL levels is essential to preventing CVD. The literature revealed several disparities in CVD treatment faced by the AA community and highlighted higher risk factors than their Caucasian counterparts (Carnethon et al., 2017; Cunningham et al., 2017), which can be eliminated by promoting evidence-based treatment interventions that improve compliance within this demographic.

This project is an evidence-based project. Based on the review of the literature, the project will focus on three evidence-based interventions in the CVD bundle that have proven effective in improving cardiovascular health for AA adults. These are medication adherence, physical activity, and eating healthy.

Medication Adherence

A review of the literature examines how interventions in primary care settings, such as health coaching (HC), benefit AAs with multiple chronic health conditions. Bailey et al. (2020) (see Appendix B) studied the effectiveness of low-cost patient-centered interventions, like HC and text messaging (TM), in improving self-care outcomes among AA patients with diabetes mellitus and other chronic illnesses in medically underserved areas. The study was a randomized controlled trial (RCT), and data were collected using questionnaires, interviews, and hemoglobin A1C levels, with a total of 581 AA adult participants. The study by Bailey et al. (2020) clearly shows that although HC and TM are practical and affordable teaching methods, they both need to be enhanced by tailoring them to the target population. In addition, Blalock et al. (2019) (see Appendix B) conducted a cross-sectional study of an RCT to investigate reasons for nonadherence to lipid-lowering medications. They developed profiles or classes of non-adherers based on the grounds for non-adherence to tailor more effective interventions when treating hyperlipidemia in adults. Though the study had a modest sample size of 236 adults and utilized a self-report Likert scale questionnaire and non-fasting serum cholesterol levels, it was limited to Veterans only, and some of the classes for non-adherence were unclear. Understanding the reasons behind medication non-adherence is essential, and patient education can be tailored to

each patient's reasons for better outcomes. The study by Blalock et al. (2019) shows that measuring cholesterol levels effectively monitors cholesterol medication adherence. Both studies by Bailey et al. (2020) and Blalock et al. (2019) are essential, but Bailey et al. (2020) was a more robust study as it was specific to AA adults as opposed to Blalock et al. (2019)'s study, which was limited to Veterans of all races.

Tran et al. (2022) (see Appendix B) adds more significance to using LDL monitoring to assess lipid medication adherence in a retrospective cross-sectional study conducted on 12, 322 adults with high cholesterol. Fifty percent of the participants were AAs. The study highlighted the gap in the treatment of CVD disease as lipid monitoring occurred less frequently in AA individuals in the study (odds ratio 0.78, 95% confidence interval [CI]) 0.69 to 0.89). However, some inconsistencies may have been present in the study due to missing lab orders, but it proved that lipid monitoring is an effective way to monitor lipid medication adherence. This will aid in decreasing the gap in care for the AA demographic with CVD.

Physical Activity and Eating Healthy

Increasing physical activity and eating healthy decreases obesity levels through weight reduction. A review of the literature reveals how diet in the AA culture may affect the risk for CVD. Interventions that exclude the fat-rich, sugar-sweetened drinks and processed foods prevalent in the 'soul food' diet of AA culture aid in reducing the risk for CVD. In a cohort study by Williams et al. (2021) (see Appendix B), 44 AA adults followed a vegetarian diet only. They showed significant improvement in cardio-metabolic risk factors, particularly marked reductions in weight and BMI (-10.2 lbs, 33 to 31 kg/m2, p = 0.000) and LDL (121 to 104 mg/dL, -14%, p = 0.000). Thus, weight reduction will be a valid variable in measuring the success of the project intervention.

Culturally sensitive interventions that examine attitudes and barriers to a healthy diet and physical activity in underserved or understudied populations produce positive change and reduce mortality rates from CVD. In a quasi-experimental study of 982 adults in two mainly AA neighborhoods in Pittsburgh, Pennsylvania, Vaughan et al. (2018) (see Appendix B) utilized self-reported minutes of walking measured by a physical activity questionnaire. This concept will be applied using the Rapid Assessment of Physical Activity (RAPA) questionnaire. Though the study yielded promising results on attitudes and barriers to a healthy diet and physical activity, it needed more generalizability because most of their sample were single AA women with no children. Thus, the study by Vaughan et al. (2018) did not yield helpful information compared to the study by Williams et al. (2021). This, however, should not negate the significance of examining barriers to diet and exercise.

Moore & Mary (2020) and Stormacq et al. (2020) both highlight the significance of incorporating intervention components that include cultural appropriateness, tailoring, skills building, goal setting, and active discussions to improve health-related outcomes (see Appendix B). These concepts are significant when tailoring interventions promoting physical activity and healthy eating. However, Moore & Mary's (2020) literature review study was limited to AA women and focused on holistic health therapies. Additionally, though Stormacq et al. (2020)'s systematic review of 21 studies focused on the effectiveness of health literacy interventions in increasing positive health outcomes for underserved populations, it was difficult to conclude the efficacy of the interventions due to the large number of studies involved. We can conclude that educating on diet and exercise goals will help build habits to promote healthy eating and increase physical activity levels, ultimately decreasing CVD risk factors.

Enrolling in health improvement studies promotes healthy behaviors, as evidenced by Duren-Winfield et al. (2021) (see Appendix B), who conducted a 15-week cohort study on a CVD risk-prevention and intervention course for 124 AA college students. There was an increased intake of fruits and vegetables and increased knowledge of CVD risk factors after the study, with 86 percent of the students passing the course. This is significant because educating the subjects on their risk factors and interventions to decrease CVD risk cultivates better diet and exercise practices. Halbert et al. (2017) (see Appendix B) further proved this in an RCT utilizing a comparative effectiveness education trial for lifestyle health behavior change among 530 AA adults in a metropolitan area in Philadelphia. The study concluded that education about risk factors for chronic disease and evidence-based strategies for health behavior change may help address obesity-related behaviors among AAs. Participants who completed the intervention had a 1.78 odds of meeting physical activity guidelines (95% CI= 1.02, 3.10, p = 0.04), evidence that the study yields beneficial information for reducing CVD risk factors. Though both studies produced good evidence in reviewing the literature, they also needed to be improved. Duren-Winfield et al. (2021)'s study included subjects in the age range of 17 to 26 who are relatively young and may have lower risk factors for CVD because of age; Halbert et al. (2017) study used subjective methods to measure physical activity levels and fruit and vegetable consumption versus objective approaches that are more sensitive to behavior change.

In conclusion, primary care providers should strive to include evidence-based practices incorporating health coaching, methods to increase physical activity, and healthy eating to decrease the risk for CVD in at-risk populations such as AA adults.

Project Framework

This is an evidence-based practice project. The framework used to guide this project is the Johns Hopkins Nursing Evidence-Based Practice (JHNEBP) model (Appendix D). According to Reavy (2016), it is a framework built on three cornerstones of nursing: practice, education, and research, with three steps guiding the evidence-based process: practice question, evidence, and translation, collectively called the PET process.

In the first step, the problem is identified, and an answerable practice question is developed. A systematic review and synthesis of research and non-research evidence is conducted in the second or evidence step. The third step, translation, is where an evidence-based practice team constructs a plan to implement feasible and appropriate recommendations (Dang et al., 2019).

The practice or intervention question in step one states, "In AA adults with elevated LDL levels and BMI equal to or greater than 30 kg/m², how does the use of a CVD bundle compared to standard of care improve cardiovascular health within eight weeks in a primary care clinic in Southeast Texas?" This identified the gap or problem forming the basis of the project.

The evidence in step two has been gathered through a review of the literature and synthesis of existing evidence in studies about LDL treatment in AA adults, with particular attention given to compliance with cholesterol medication treatment, physical activity and diet, and effective patient education methods tailored to this demographic. The Johns Hopkins Nursing Evidence-Based Practice Appraisal Tool was used to analyze the evidence, and best practice techniques were synthesized for this project.

The third step, or translation phase, is where the intervention is planned, constructed, and implemented utilizing appropriate recommendations to treat high LDL cholesterol in the adult

AA demographic. The project spanned eight weeks, data was collected, and the outcomes will be discussed below.

Project Question

The problem being addressed is the higher mortality rates from CVD in AA adults compared to other demographics. The project is designed to answer the following PICOTS question: In AA adults with elevated LDL levels and BMI equal to or greater than 30 kg/m², how does the use of a CVD bundle, which includes implementing cholesterol medication adherence, physical activity levels evaluations, and patient education with the use of handouts and verbal education on the effects of hearts disease, compared to standard of care, improve cardiovascular health within eight weeks in a primary care clinic in Southeast Texas? The desired outcome is a reduction in weight and LDL cholesterol measurements, improved adherence to cholesterol medication, increased physical activity levels, and increased knowledge of the effects of heart disease.

Methods

Setting

The Doctor of Nursing (DNP) project was conducted in a primary care clinic in Southeast Texas. The clinic operates six days a week and is staffed with one physician, three nurse practitioners, two clerical staff, and three medical assistants. It is centrally located in a commercial space with easy accessibility and adequate patient parking spaces. The clinic has inhouse laboratory testing, four patient examination rooms, and enough space for expansion. Their mission is to provide accessible, high-quality care and promote the health and well-being of the community. The providers see approximately 35-45 patients daily, with 40 percent of the patients being of AA heritage. The clinic provides primary care services such as annual physicals, sick visits, minor emergency visits, urgent care, weight loss, intravenous hydration therapy, sports physicals, and immunizations. Primary care providers had the tools to screen patients for diseases and conditions that increased the risk for comorbidities and severe illnesses like CVD and stroke. Phlebotomy services were provided in the clinic for bloodwork for this project. If the clinic could not perform on-site lab draws, a paper lab order was provided to the patient for bloodwork at an outpatient LabCorp site. Effective management of CVD risk factors such as obesity and high cholesterol decreases the risk of developing CVD, an essential element for AAs who have higher overall CVD mortality and premature death rates than Caucasians (Bacon, 2020). This setting served as an excellent data source and allowed for the application of the project to mitigate this gap in care.

Population

Heart disease is the number one cause of adult mortality in the USA (CDC, 2022). It affects men and women of all races, but different mortality rates exist for various demographic groups. The target population in focus was non-Hispanic African American (AA) adults, male and female, with a BMI of 30 kg/m^2 and over and LDL levels above 100 mg/dl.

Participants included established and new patients who met the inclusion and exclusion criteria. The anticipated sample size for the project was 40 patients. The patients were recruited when they came in for a clinic visit. The inclusion criteria were that the patients' abnormal LDL levels should have been collected in the last 12 months in an outpatient or acute care setting. They should have already been prescribed a cholesterol-lowering medication. The patients were able to speak, read, and comprehend the English language. Exclusion criteria for the population

include pregnancy, incarceration, mental illness, cognitive dysfunction, major CVD events such as myocardial infarction and stroke in the last three months, and cardiac stent placement in the previous three months. Weight was measured at the beginning and end of the project using a digital standing scale in the clinic. At the end of the project, LDL levels were rechecked through laboratory testing in the primary care clinic. Racial and ethnic data were collected through a questionnaire on demographics.

Team Role

The clinic operates six days a week and is staffed with one physician, three nurse practitioners (NP), two clerical staff (clerks), and three medical assistants (MA). The NP conducting the project is the Project Lead. The physician was the administrator. The team was comprised of the project lead NP, NP1, NP2, MA1, MA2, Clerk 1(C1), and Clerk 2 (C2). The project lead guided the project and delegated data collection portions to the other team members. The project lead and NPs invited patients into the project and explained the purpose, steps, and duration. The project lead and the NPs also ensured the participants completed the MARS-5 and RAPA questionnaires and a Heart Disease Knowledge Survey. Each participant received a patient education pamphlet to guide them as they followed the diet and exercise recommendations at home for the duration of the project. Weight measurements were collected at the beginning and end of the project and documented in the electronic medical record (EMR).

MA1 and MA2 made initial contact with the patient in the exam room. They collected weight measurements and placed the questionnaire forms and education pamphlets in the exam room. The NPs and project lead invited the patients to participate by reading a project invitation script (Appendix E). MA1 and MA2 assisted with collecting the completed questionnaires at the end of the visit. In addition, the MAs were also educated on the importance of the project to answer questions from patients interested in participating.

NP1 and NP2 invited patients to participate in the project when they determined they met the criteria. Suppose the project lead could not see the participant during the visit, NP1 and NP2 followed the project invitation script included in the DNP Project Team Education PowerPoint handout in Appendix F. If the patient agreed to participate, the NP ensured the participants completed the questionnaires. They gave each participant the patient education pamphlet. They documented the weight and LDL values in the database dashboard. After the visit, C1 and C2 scheduled the participants' 8-week follow-up appointments for the project-end visit. The administrator served as a resource to the project lead. He assisted by clarifying aspects of the project where needed and reviewed the participants' health records to ensure the accuracy of inclusion and exclusion criteria, data collection, completeness of forms, and prevention of Health Insurance Portability and Accountability Act (HIPPA) violations in the data collection process.

Education of the Team

It was essential to educate the team members on their roles in making this project run smoothly. The team needed to understand the basis of the project to help implement it effortlessly. The MAs who usually made initial contact with the patient in the exam room were educated on correctly measuring and documenting the weight and on the overall importance of the project. The MAs and NPs were provided with a project invitation script to follow that included general information about the project to be used to invite patients to participate. The NPs ensured each participant met the inclusion criteria to qualify as a participant. The team was educated on the importance and significance of all project components. The project lead educated the team using the PowerPoint presentation (Appendix F) handout. The patients completed the patient questionnaires, and each participant received the patient education pamphlet. Copies of all the documents used in the project were available for the team to provide to the participants. Each participant received a call from the project lead every two weeks to ensure they stayed on track, answered any questions about their progress, and reminded them of their post-project visit. The Lead, C1, and C2 facilitated this part of the project. The project lead met with the team every two weeks to ensure the project went as planned and answered questions the team had concerning the project. A GANTT chart was created to illustrate the implementation of the project over the 8-week project duration (Appendix G).

Implementation

Two days before the implementation process, the team was educated on the project purpose, data collection, and their roles in the implementation process. The project lead conducted a 30-minute education session during the team lunch break using the Project Team Education PowerPoint (Appendix F). The lead answered questions from the team and offered clarification where needed. Printed copies of the PowerPoint slides were provided to the team for reference.

The project commenced on day three of the first week. Patients who met the criteria for participation met with the project lead and other NPs for a 20-minute pre-survey data collection and educational session. Participants completed the MARS-5 questionnaire (Appendix H), the RAPA questionnaire (Appendix I), and the Heart Disease Knowledge Survey (Appendix J). The MA or NP weighed each participant. After completing the pre-test surveys, each participant received the Heart Disease Educational Pamphlet (see Appendix K). The NP educated the patient on LDL medication adherence, physical activity, and diet recommendations to reduce their risk for heart disease. These recommendations were to be followed for the project duration and were included in the education pamphlet. The session concluded with the project lead, or NP, confirming LDL values and weight measurements and ensuring they were documented in the electronic health record (EHR). This data was manually inputted into the dashboard spreadsheet by the NPs. After the session, the Clerk scheduled a 20-minute post-project visit during weeks 6 to 8 of the project. Completed forms were placed in a secure drawer and locked by the project lead.

Every two weeks after a participant enrolled in the project, the project lead placed a follow-up call to check on their progress, reminded them of their post-project visit, and answered any questions the participants had about the project. An appointment reminder was sent to participants who were unreachable by phone, and the project lead placed another reminder phone call a week before their post-project visit. At the post-project visit, each participant had their LDL values measured by blood draw in the clinic laboratory and had their post-project weight measurements obtained by the MAs. The participants completed the MARS-5 and RAPA questionnaires and the Heart Disease Knowledge Survey for post-project data collection. Finally, the project lead collected the data from the pre/post-test questionnaires and pre/post-LDL and weight measurements for analysis.

Data Collection and Dashboard

Data collection began when a patient agreed to participate in the project. The data collection process involved collecting basic demographic information about the participants, including age, gender, employment status, marital status, and education level (Appendix L). Preintervention and post-intervention test results of LDL values, weight, MARS-5 questionnaire responses, and RAPA questionnaire responses were also collected. Pre-intervention test results were collected at the beginning of the project, and post-intervention test results were collected. during week eight. Each participant was assigned a patient identification code (28-19-006, 10-15-007, etc.) corresponding with their pre-and post-test questionnaires, LDL, and weight measurements. The last three digits of the code assigned to each participant corresponded with the order in which they were recruited by the project lead or the NP who explained the project to them. The project lead added five points to the three-digit number to mask the patient's identity; thus, the first patient's three-digit code was 006. The project lead assigned the patient code to a master-participant list. Only the project lead had access to the master participant list, which was kept in a locked cabinet in the project lead's office, which was also kept locked. Since the questionnaires were in paper format, the project lead collected and secured all surveys in the locked drawer until all the data was entered on the dashboard, after which the project lead shredded them. The database dashboard (Tables Q1 and Q2, and Q3 in Appendix M) contained the coding categories and the aggregated data from the outcome variables collected during the project. Refer to Appendix N for the participant identification master coding system and Appendix O for the database coding legend for data analysis. Data was stored in an Excel File, as reflected in Appendix O, which was stored on the University of Texas Arlington (UTA) OneDrive on a password-protected laptop computer in the project lead's home office kept behind locked doors.

The administrator, clerks, MAs, and NPs were educated on all project steps before initiation. The MAs assisted with data collection by ensuring participants were weighed correctly and measurements were documented in the patients' charts. The MAs also collected the completed questionnaire forms. The NPs aided in data collection by documenting weight and LDL values in the database dashboard and collected completed forms for storage in the locked drawer. The project lead and NPs explained the intervention to the participants and reviewed the patient education pamphlet with each participant, who retained a copy. The MAs were educated in obtaining and documenting accurate weight measurements. The NPs were educated on the content of the questionnaires using the dashboard and education pamphlets, and they assisted with data collection and documentation on the dashboard.

Data Analysis

Data analysis for the project utilized descriptive statistics, which revealed specific characteristics within a sample data set and illustrated project variables (Grove & Cipher, 2020). Data analysis involved processing pre-test and post-test variables of LDL, weight, MARS-5, RAPA, and the Heart Disease Knowledge survey questionnaire responses of one group of participants. The data was inputted into the Statistical Software for the Social Sciences (SPSS) software for calculation and analysis. SPSS analyzed the demographic data collected to gain additional information that added significance to the project results. The participant demographic data included age, gender, marital status, employment status, and educational level. They were analyzed for frequencies, frequency distributions, and percentages using SPSS. All demographic variables except age were examined using the nominal scale. Age was recorded as a ratio value with frequencies such as the average age of participants at enrollment calculated.

LDL and weight outcome variables were analyzed in SPSS using the Paired Samples Ttest or repeated measures test. LDL and weight measurement data, both ratio levels of measurement, were processed for the mean differences using the paired samples t-test. The Wilcoxon Signed-Rank test, a non-parametric data analysis method, was used instead of the repeated measures test to analyze the MARS-5 and RAPA questionnaire responses since this data was ordinal and paired from the same sample. The MARS-5 assessed the participants' adherence to cholesterol medications, while the RAPA questionnaire assessed their physical activity levels. The pre-test and post-test questionnaire outcomes were examined using percentages, frequencies, and means (Grove & Cipher, 2020). The project lead collaborated with a statistician for assistance in analyzing the results.

Results

Participant Description

When the project implementation phase began, 40 participants completed the preintervention data collection; 19 returned to the clinic and completed the post-intervention data collection process. 57.9 percent of the 19 retained participants were female, with 42.1 percent male. 42.1 percent were married, and 21.6 percent of the participants were either divorced or widowed. 52.6 percent were unemployed, 36.8 percent had a high school degree or less, and 26.3 percent had an Associate degree or were Masters level educated.

Outcome Results

Analysis of the results indicated the effects of the CVD bundle produced statistically significant scores in five of the six data pairs, which were cholesterol medication adherence, LDL levels, physical activity, and heart disease education, with p<0.001 in these areas. The intervention was not statistically significant in weight measures with p<0.025.

Adherence to cholesterol medication was assessed using the MARS-5 questionnaire composed of Likert-type items, with responses ranging from 1 to 5, with 1=always to 5=never, as shown in (Appendix H). The average score or mean (M) of medication adherence before the intervention was 14.26 and 19.11 after the intervention. This represented an increase in cholesterol medication adherence post-intervention.

The level of physical activity was assessed using the RAPA questionnaire, which has two sections, as shown in (Appendix I). For the RAPA-1 questionnaire, before the intervention,

participants had a mean score of 2.79 and 4.21 after the intervention. For the RAPA-2 questionnaire, participants had a mean score of 0.53 before the intervention and 1.05 afterward. This indicates that participants' physical activity levels increased after the intervention.

Knowledge about cardiovascular disease was assessed using the Heart Disease Education survey, as shown in (Appendix J). Before the intervention, participants had a total preeducation mean score of 8.58 and 14.26 after. This indicates an increase in participant knowledge of heart disease after the intervention.

Participants' weights in pounds and LDL cholesterol levels in mg/dl were also assessed pre-and post-intervention. Before the intervention, participants had an average weight of 202.442 pounds and 197.311 pounds post-intervention. Finally, before the intervention, participants had a mean LDL level of 139.21 mg/dl and 130.84 mg/dl post-intervention. This indicates participants had an overall reduction in weight and LDL levels because of the intervention (Appendix P).

A paired samples t-test and Wilcoxon Signed-Rank test revealed significant differences between all six data pairs pre-intervention and post-intervention scores. For the medication adherence using MARS-5, t (18) =-8.024, p<0.001. For physical activity level measures, RAPA-1, t (18) = 7.435, p<0.00, with RAPA-2, t (18) =13.568, p<0.001. For the weight measurements, t (18) = 2.105, p<0.025. For the LDL values, t (18) =5.079, p<0.001. And finally, for the total heart disease education scores, t (18) = -18.000, p<0.001. Thus, the intervention had a statistically significant impact on the participants in all data pairs except for weight, where p< 0.025 was above the statistically significant value of 0.01. This indicates the CVD bundle intervention successfully improved cardiovascular health in the participants compared to standard care. Unexpected problems included several canceled post-intervention data collection clinic visits that reduced the sample size by over 50%. The final 19 participants completed all aspects of the project with no missing data.

Discussion

Statistically reliable improvements in cholesterol medication adherence, LDL levels, physical activity, and heart disease education were noted in the post-intervention data. This is significant for the primary care clinic as it indicates that using the CVD bundle improved heart health in the participants compared to standard care. For the AA adult population, this indicates that tailored interventions beyond standard care can reduce their risk for heart disease, and therefore prolong their lives. Consequently, the use of the CVD bundle will be continued in the clinic. Improving heart health in this demographic decreases the national mortality rate from CVD, thus improving the health of the nation, decreasing healthcare costs, and improving the quality of life for AA individuals and their families and communities. Similarly, Bailey et al.'s 2020 study indicated that targeting a specific demographic allowed for the results to be generalizable to similar underserved populations where they applied the use of questionnaires and biological measurements to determine the effectiveness of their intervention.

The strengths of the study included exclusion criteria that participants from volunteering in the study would not be able to complete the questionnaires independently or follow all requirements to participate in the project successfully. Additionally, the project included the participants not incurring extra costs for participation, and all resources required were present in the clinic. Some modifications that will be made to the intervention include placing the questionnaires in electronic form for patient preference, which may reduce the time spent filling out the paperwork. Study weaknesses include the threat to the internal validity of maturation. It allowed the participants to predict that better responses would indicate better outcomes since the same questionnaires were utilized in the pre-and post-intervention phases. In addition, outside interference or histories, like weight loss medications or natural supplements to reduce cholesterol, may have contributed to weight loss and reduced LDL measures outside the intervention alone. Efforts made to reduce these limitations included participants returning completed questionnaires to staff and not retaining copies for review prior to the post-intervention data collection appointment. Participants were also encouraged to give truthful responses to the questions.

The limitations of the project include sampling of adults from one demographic, which was AA adults, thus reducing its generalizability to other demographics. Also, the sample size 19 was small and may not necessarily be generalizable to a bigger group of participants. The Hawthorne effect also reduces the generalization of results as the participants were aware of being studied with an expectation of better responses and measurements in the post-intervention phase for the success of the intervention. Another limitation is the length of the study; eight weeks may not be sufficient to determine if the medication adherence, increase in physical activity, decrease in LDL cholesterol, and decrease in weight measurements would be sustained over a more extended period. Future nurse scientists looking to close these gaps in the project may look to have a larger sample size and collect measurements over a more extended period.

In conclusion, cumulative evidence supports the significant impact the CVD bundle had on the participants' heart disease risk. The CVD bundle was found to reduce the overall weight of the participants and clinically significantly increased their adherence to cholesterol medication, increased their heart disease knowledge, decreased their LDL measurements, and increased their physical activity levels. This implies embedding the CVD bundle into practice in primary care settings will decrease morbidity and mortality from heart disease in AA adults. Further research is warranted with a larger sample size over a subsequently more extended period to investigate if the short-term improvements are sustainable for AA adults.

References

America's Health Rankings. (2022). Annual report. https://www.americashealthrankings.org/explore/measures

- Bacon, E. (2020). Racial/ethnic differences in treatment recommendations: Lifestyle changes and medication prescriptions for high cholesterol. *Ethnicity & Health*, 25(2), 273–288. https://doi.org/10.1080/13557858.2017.1398315
- Bailey, J. E., Surbhi, S., Gatwood, J., Butterworth, S., Coday, M., Shuvo, S. A., Dashputre, A. A., Brooks, I. M., Binkley, B. L., Riordan, C. J., Steinberg, H. O., Gutierrez, M. L., Haley, L. E., Leak, C. L., & Tolley, E. A. (2020). The management of diabetes in everyday life study: Design and methods for a pragmatic randomized controlled trial comparing the effectiveness of text messaging versus health coaching. *Contemporary Clinical Trials*, *96*, 106080. https://doi.org/10.1016/j.cct.2020.106080
- Blalock, D. V., Bosworth, H. B., Reeve, B. B., & Voils, C. I. (2019). Co-occurring reasons for medication nonadherence within subgroups of patients with hyperlipidemia. *Journal of Behavioral Medicine*, 42(2), 291–299. https://doi-org.ezproxy.uta.edu/10.1007/s10865-018-9954-3
- Carnethon, M. R., Pu, J., Howard, G., Albert, M. A., Anderson, C. A. M., Bertoni, A. G., Mujahid, M. S., Palaniappan, L., Taylor, H. A., Willis, M., & Yancy, C. W. (2017).
 Cardiovascular health in African Americans: A scientific statement from the American Heart Association. *Circulation*, *136*(21), e393–e423. https://doi.org/10.1161/CIR.00000000000534
- Centers for Disease Control and Prevention. (2019). *About high blood cholesterol*. https://www.cdc.gov/cholesterol/about.htm

Centers for Disease Control and Prevention. (2020). Heart Disease and stroke.

https://www.cdc.gov/chronicdisease/resources/publications/factsheets/heart-diseasestroke.htm#:~:text=Leading%20risk%20factors%20for%20heart

Centers for Disease Control and Prevention., & National Center for Health Statistics. (2021). National vital statistics system, mortality 1999-2020 on CDC WONDER online database. https://wonder.cdc.gov/controller/saved/D76/D266F218

Centers for Disease Control and Prevention. (2022). *Heart disease facts*. https://www.cdc.gov/heartdisease/facts.htm

- Centers for Disease Control and Prevention. (2023). *Celebrate African American history month!* https://www.cdc.gov/healthequity/features/african-americanhistory/index.html#:~:text=However%2C%20certain%20groups%E2%80%94including %20African
- Chan, A. H. Y., Horne, R., Hankins, M., & Chisari, C. (2020). The medication adherence report scale: A measurement tool for eliciting patients' reports of nonadherence. *British Journal of Clinical Pharmacology*, 86(7), 1281–1288. https://doi.org/10.1111/bcp.14193
- Cunningham, T. J., Croft, J. B., Liu, Y., Lu, H., Eke, P. I., & Giles, W. H. (2017). Vital signs:
 Racial disparities in age-specific mortality among Blacks or African Americans —
 United States, 1999–2015. *MMWR. Morbidity and mortality weekly report*, 66(17), 444–456. https://doi.org/10.15585/mmwr.mm6617e1
- Duren-Winfield, V., Carr, L. T. B., McCauley, G. A., Onsomu, E. O., Roberson, K., Williams, J., Kizakevich, P. N., Krzyzanowski, M., & Price, A. A. (2021). The development and pilot testing of an evidence-based cardiovascular disease risk-prevention program to promote healthy lifestyle behaviors among African-American college students – Rams Have

HEART. Journal of Best Practices in Health Professions Diversity: Research, Education and Policy, 14(1), 44–62.

Dyke, M. V. (2018). Heart disease death rates among Blacks and Whites aged ≥35 Years — United States, 1968–2015. *MMWR*. *Surveillance summaries*, 67. https://doi.org/10.15585/mmwr.ss6705a1

- Grove, S., & Cipher, D. (2020). *Statistics for nursing research: A workbook for evidence-based practice*. Elsevier Health Science.
- Halbert, C. H., Bellamy, S., Briggs, V., Delmoor, E., Purnell, J., Rogers, R., Weathers, B., & Johnson, J. C. (2017). A comparative effectiveness education trial for lifestyle health behavior change in African Americans. *Health Education Research*, 32(3), 207–218.
- Heron, M. (2021). National vital statistics reports deaths: Leading causes for 2019. https://www.cdc.gov/nchs/data/nvsr/nvsr70/nvsr70-09-508.pdf
- Houston Health Department. (2019). *Health disparity and health inequity 2019 trends and data report Houston/Harris county*. https://www.houstontx.gov/health/chs/documents/Health-Disparities-Summary-2019.pdf

Houston State of Health. (2023). Disparities dashboard.

https://www.houstonstateofhealth.com/indicators/index/dashboard?alias=disparities

Lee-Frye, B. (2022). *Cholesterol, heart disease, and African Americans*. Verywellhealth. https://www.verywellhealth.com/cholesterol-heart-disease-and-african-americans-3571756#:~:text=The%20association%20reports%20that%2032.4,high%20or%20high% 20LDL%20levels

Magriplis, E., Sialvera, T. E., Papadopoulou, A., Efstathiou, S. P., Trautwein, E. A., Goumas, G.,

Dimakopoulos, I., Papavasiliou, K., Koutsouri, A., & Zampelas, A. (2019). Effectiveness and easiness of adherence to behavioural guidelines for diet and lifestyle changes for cholesterol-lowering: The Increasing Adherence of Consumers to Diet & Lifestyle Changes to Lower (LDL) Cholesterol (ACT) randomised controlled trial. *Journal of Human Nutrition and Dietetics: The Official Journal of the British Dietetic Association*, *32*(5), 607–618. https://doi-org.ezproxy.uta.edu/10.1111/jhn.12667

- Mayo Clinic. (2021). *Obesity*. https://www.mayoclinic.org/diseasesconditions/obesity/symptoms-causes/syc-20375742
- Miszory, E. V., Makai, A., Pakai, A., & Járomi, M. (2022). Cross-cultural adaptation and validation of the rapid assessment of physical activity questionnaire (RAPA) in Hungarian elderly over 50 years. *BMC Sports Science, Medicine & Rehabilitation, 14*(1), 131. https://doi.org/10.1186/s13102-022-00512-3
- Moore, T. L., & Mary, A. (2020). Medication compliance and holistic complementary alternative therapies among African American women with chronic conditions: A literature review. *ABNF Journal*, *31*(2), 54–60.
- Nanna, M. G., Navar, A. M., Zakroysky, P., Xiang, Q., Goldberg, A. C., Robinson, J., Roger, V. L., Virani, S. S., Wilson, P. W. F., Elassal, J., Lee, L. V., Wang, T. Y., & Peterson, E. D. (2018). Association of patient perceptions of cardiovascular risk and beliefs on statin drugs with racial differences in statin use. *JAMA Cardiology*, *3*(8), 739–748. https://doi.org/10.1001/jamacardio.2018.1511
- Reavy, K. (2016). Evidence-based practice: Background and models. In Reavy, K. (Ed.), *Inquiry and leadership: A resource for the DNP project*. (Pp. 43–57). Philadelphia, PA: F.A. Davis Company.

- Stormacq, C., Wosinski, J., Boillat, E., & Van den Broucke, S. (2020). Effects of health literacy interventions on health-related outcomes in socioeconomically disadvantaged adults living in the community: A systematic review. *JBI Evidence Synthesis*, *18*(7), 1389– 1469. https://doi.org/10.11124/JBISRIR-D-18-00023
- Tran, C., Vo, V., Taylor, P., Koehn, D. A., Virani, S. S., & Dixon, D. L. (2022). Adherence to lipid monitoring and its impact on treat intensification of LDL-C lowering therapies at an urban academic medical center. *Journal of Clinical Lipidology*, *16*(4), 491–497. https://doi-org.ezproxy.uta.edu/10.1016/j.jacl.2022.05.003
- USA Health Rankings (2022). USA coronary heart disease death rate by state. https://www.worldlifeexpectancy.com/usa/heart-disease
- US Department of Health and Human Services. (2019). *Obesity the office of minority health*. Hhs.gov. https://minorityhealth.hhs.gov/omh/browse.aspx?lvl=4&lvlid=25
- Vaughan, C. A., Ghosh-Dastidar, M., & Dubowitz, T. (2018). Attitudes and barriers to healthy diet and physical activity: A latent profile analysis. *Health Education & Behavior*, 45(3), 381–393.
- Williams, K. A., Fughhi, I., Fugar, S., Mazur, M., Gates, S., Sawyer, S., Patel, H., Chambers, D., McDaniel, R., Reiser, J. R., & Mason, T. (2021). Nutrition intervention for reduction of cardiovascular risk in African Americans using the 2019 American College of Cardiology/American Heart Association primary prevention guidelines. *Nutrients*, *13*(10), 3422. https://doi.org/10.3390/nu13103422

World Health Organization. (2022a). Cardiovascular diseases.
https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1
World Health Organization. (2022b). Indicator metadata registry details.

https://www.who.int/data/gho/indicator-metadata-registry/imr-details/3416

Appendix A

Whites	Blacks	Whites	Blacks	Whites	Blacks
35-44	35-44	45-54	45-54	55-64	55-64
23.8	56.8	76.7	143.3	187.1	330.7

Heart Disease Mortality Rates Per Age Group Table

Note. Summary of heart disease death rates in 2019 from Heron et al. (2021).

Appendix B

Evidence Table

#	Author Citation	Design & aim or hypothesis & Major Variables	Population & Setting & Sample Size	Intervention	Measurements (e.g., tool to assess outcome)	Results &/OR Recommendatio ns	Strengths & Limitations	Evidenc e Level & Quality Rating
1	Bailey	Randomized	AA adults aged	TM and	- SDSCA	Recommendation	Strength:	Level II
	et al.	Control Trial	18 years and	HC	questionnaire	S:	Using AA	
	(2020)	(RCT)	over with		_	- assist health	patients with	Quality
			uncontrolled		- Treatment	systems in	uncontrolled	Rating:
		Hypothesis-	diabetes		Self-Regulation	understanding	diabetes will	В
		subgroup	living in		Questionnaire	the contextual	allow for the	
		analyses for	medically		(TSRQ)	factors of	generalization of	
		heterogeneity of	underserved		Distance 20	underserved	the results to	
		treatment	areas of the		- Diabetes-39	populations that	similar	
		effects will show that HC is	Mid-South		quality of life instrument	drive intervention	underserved	
		superior to TM	N= 581		Instrument	effectiveness	populations, such as AAs	
		for higher-risk	IN- J01		- Perceived	- to tailor and	with CVD and	
		subgroups with			Competency	replicate findings	hyperlipidemia.	
		low health			Scale	to similar	nypernpidenna.	
		literacy, high			Seule	populations.	- examining HC	
		medical or			- Adherence to	populations.	(low-cost) to	
		social			Refills and		TM (higher	
		complexity,			Medications		cost) will enable	
		non-smart cell			Scale		healthcare	
		phone					providers to	
		ownership,			- A1c obtained		assess the	
		older age, and			from medical		utilization of	
		suburban/rural			records and		combinations of	

residence		reported in the	interventions for
(Bailey et a	••	DWPC	AAs.
2020).		Registry	
		(Bailey et al.,	Limitations:
Major varia	oles	2020).	- the model only
- general di	et,		tests two
exercise,			primary care
medication			interventions.
adherence,			- Other AA
primary car			patients in
engagemen			underserved
average blo			areas may not
sugar (A1c			have similar
			healthcare
			experiences in
			other parts of
			the country,
			reducing the
			possibility of
			generalization of
			the results.
			- recruitment
			was limited to
			AAs in
			outpatient
			populations, a
			missed
			opportunity to
			involve
			medically
			underserved
			inpatients

2	Blalock et al.	Design: Cross- sectional study	Population: adults with	- A multi- component,	- Self-report Likert scale on	- Non-fasting serum total	Strength: - four distinct	Level III
	(2019).	of an RCT	hyperlipidemia	tailored	non-adherence	cholesterol was	classes of	Quality
	(2017).		nypeinpideinid	behavioral	- Non-fasting	positively	medication non-	Rating:
		Aim: to inform	Setting- three	intervention	serum	correlated with	adherers were	В
		patient care by	primary care		cholesterol	the endorsement	identified.	
		providing a	clinics affiliated		laboratory	of non-adherence	- Interventions	
		mechanism to	with the		values were	(Blalock et al.,	can be tailored	
		identify profiles	Durham		measured.	2019, p. 293).	using these	
		of nonadherence	Veterans Affairs			-	classes to	
		behaviors and	Health Care			- endorsed	improve	
		target	System			reasons for non-	medication	
		interventions to				adherence were	adherence when	
		improve	N=236			forgetting (58%,	treating	
		adherence in				n = 63), worried	hyperlipidemia.	
		individual				about taking	-examination of	
		patients.				medications for	the classes	
		NG 1 1 1				the rest of one's	supported the	
		Major variables:				life $(30\%, n = 22)$ has an (26%)	validity and	
		occasional				33), busy (26%, $n = 28$), aida	generalization of	
		forgetful adherers, side				n = 28), side effects (25%, n =	the findings	
		effect non-				27), coming	Limitations:	
		adherers, and				home late (25%,	- modest sample	
		out-of-routine				n = 27), and	size	
		non-adherers				traveling (23%, n	- the	
						= 25) (Blalock et	categorization	
						al., 2019, p. 293).	for the side-	
						· · · · · · · · · · · · · · · · · · ·	effect non-	
						- the two least	adherence class	
						reported reasons	is unclear; it	
						for non-	may be due to	
						adherence were	patients	

					cholesterol being	stopping the	
					too low (5%, n =	medication on	
					5) and costing	their own or	
					much money	following the	
					(7%, n = 8)	doctor's orders	
					(Blalock et al.,	to stop the	
					2019, p. 293)	medicine.	
					-	- single time	
					- multimodal	items were used	
					interventions that	in the latent	
					involve patient	analysis of the	
					education and	classes, but	
					collaborative	medication non-	
					planning should	adherence may	
					be tailored to the	be a time-	
					patient's reason	varying	
					for	phenomenon;	
					noncompliance.	thus, results may	
					•	not be accurate.	
3 Duren-	Design: Cohort	Population &	An evidence-	- The Queen's	Results:	Strengths:	Level
Winfiel	study	setting: AA	based, 15-	College Step	- mean blood	- applicable	IV
d et al.	·	college students	week CVD	Test was used	lipid panel and	translation to	
(2021)	Aim:	at a	risk-	to assess	glucose results	other settings	Quality
	- assess CVD	Southeastern	prevention	cardiovascular	were within the	with populations	Rating:
	risk factors	HBCU	and	fitness.	optimal range for	at high risk for	В
	among AA		intervention		the study.	CVD	
	college students		program/cours	- Personal	- Intake of fruits	- high potential	
	by examining	N=124	e.	Health	and vegetables	for	
	blood markers.			Intervention	increased	generalizability	
	- to pilot test the			Tool (PHIT)-	- knowledge of	and impact	
	effects of a 15-			used to record	CVD risk factors	- The study	
	week CVD risk-			daily recall of	increased	provided tools	
	prevention			food and drink	- 86% of the	for students to	

intervention	consumption,	students enrolled	monitor their
administered as	mainly fruits	in the	health behaviors
a 3-credit hour	and vegetables,	intervention	and continue to
course versus a	and document	group passed the	improve their
control course	physical	course.	health over time,
on two cohorts	activity.		reducing risk
of AA college		Recommendation	factors for
students (Duren-	Other	- Developing and	chronic
Winfield et al.	questionnaires	offering a healthy	diseases.
(2021).	administered:	lifestyle-behavior	
	- Pittsburgh	CVD	Weaknesses:
Hypothesis:	Sleep Quality	intervention	- Limited
students	Index (PSQI),	course to AA	retention of
enrolled in the	- Perceived	college students	college students
evidence-based	Stress Scale	effectively	in the post-
CVD health	(PSS-10)	maximizes their	assessment
curriculum will	- International	awareness of	phase.
adopt better	Physical	chronic disease	- loss of follow-
health behaviors	Activity	risk factors and	up data on
and improve	Questionnaire	prompts behavior	students who
their	(IPAQ)	change (Duren-	did not return to
anthropometric	- Rams Have	Winfield et al.,	school after
measurements	Heart App	2021).	winter or
(BMI) and waist	Evaluation		summer breaks
circumference)	Questionnaire		(Duren-Winfield
and blood			et al., 2021).
markers (total			
cholesterol,			
triglycerides,			
high-density			
lipoprotein			
[HDL], low-			
density			

4	Halbert et al. (2017)	lipoprotein [LDL], and glucose, compared to the control group not enrolled in the course. Major variables: IV- the CVD risk-prevention intervention course. DV1- anthropometric measurements DV2- blood makers RCT Aim: To compare the effects of integrated (INT) versus disease- specific education (DSE) on changes in obesity-related	Population & setting: AA adults aged 18- 75 residing in the Philadelphia, PA, metropolitan area. N= 530	A comparative effectiveness education trial for lifestyle health behavior change (Halbert et al., 2017).	Health Information National Trends Survey (HINTS) to evaluate FV intake and PA	- Significant increases were found in the proportion of participants who met PA guidelines from baseline (47.4%) to follow-up (52.4%) (p= 0.005).	Strengths: - using a CBPR approach to develop, implement, and evaluate intervention protocol - most participants completed the	Level II Quality Rating: A
		specific education (DSE) on changes in	area.	change (Halbert et al.,	intake and PA	baseline (47.4%) to follow-up (52.4%) (p=	protocol - most participants	

	among African				guidelines (95%	- Completion of	
	Americans				CI= 1.02, 3.10, p	the study may	
	Halbert et al.				= 0.04).	be affected by	
	(2017).				- Education	the financial	
					about risk factors	incentive at	
	Major variables:				for chronic	completion and	
	PA and FV				disease and	may not be	
					evidence-based	replicable in	
					strategies for	future studies	
					health behavior	- no objective	
					change may help	methods were	
					address obesity-	used to measure	
					related behaviors	PA or FV, just	
					among African	subjective	
					Americans.	reports, which	
					7 micricans.	may not be	
						sensitive to	
						behavior	
						change.	
						0	
						- follow-up retention rates	
						could have been	
						higher, possibly	
						due to no	
						financial	
						incentive to	
						complete	
						follow-ups.	
5 Magripli	RCT	Adults aged 45	Randomized	- The	Results: DG	Strength: Using	Level II
s et al.		to 75 years old	6-week study	International	group showed	evidence-based	
(2019)	Aim: to assess	with	with	Activity	higher adherence	behavioral	Quality
	the effectiveness	hyperlipidemia	behavioral	Questionnaire –	scores to diet,	change	Rating:
	and easiness of	who were	therapy	Short Form to	lifestyle change,	strategies could	Α

behavioral, diet, and lifestyle changes related to hyperlipidemia given by physicians or dieticians where those changes have been previously difficult to sustain. Major variables: perception of easiness, effectiveness, and future adherence, BMI, BP, and cholesterol values.	inhabitants of Athens and its surroundings. Setting- professional primary care setting N= 100	sessions administered by a physician group (PG) or a dietitian group (DG).	assess PA - Weight and height measurements to calculate the BMI - The 'forecasted adherence' questionnaire - A basic cholesterol knowledge questionnaire - IPAQ questionnaire - BP measurement and blood sample collection to measure cholesterol values - Questionnaire for perceived effectiveness of adhering to guidelines - Questionnaire for perceived easiness with respect to	and perception of cholesterol- lowering and easiness of following than the PG group. Recommendation s: - Lifestyle and dietary changes related to HLD can be achieved with monitoring and continuous education. - a multidisciplinary approach involving dietitians for follow-up will enhance the lifestyle and dietary changes for adults with dyslipidemia.	increase the effectiveness of treating HLD and incorporate technological interventions. - The study indicates that a multidisciplinar y approach to treating HLD by including dietitians is optimal. Weakness: short duration of the study may limit the time to develop multiple behavior change techniques or provide long- term efficacy of diet and behavioral changes for HLD patients whose condition involves lifelong change.

					adhering to guidelines - Questionnaire for effectiveness with respect to adhering to guidelines - Questionnaire for easiness with respect to adhering to guidelines - Questionnaire for reported			
6	Moore & Mary (2020)	Literature Review Aim: "to examine the inclusion of holistic health therapies for AA	AA women aged 18-99 years old with any chronic conditions. N= 10 articles	- Holistic nurse coaching sessions - one-on-one interviews - focus groups	forecasted adherence - Symptom Status Questionnaire - Heart Failure, Minnesota Living with Heart Failure Questionnaire,	-The review indicated an openness of AA women to include CAT in their medical treatment plans. - Non-	Strengths - a focus on studies about AA women examined data often overlooked, where men are	Level VII Quality Rating: B
		women with chronic conditions" (Moore & Mary, 2020, p. 54) <u>Major variables:</u>		questionnaires	 Patient Health Questionnaire - 9, Control Attitudes Scale Revised, - 	compliance may result from including some aspects of religion or spirituality. - AA women use	usually the majority in most studies. - it revealed factors AA women value in treatment that	

Medication	Multidimension	multiple home	will enable
compliance and	al Scale of	remedies and	providers to
Holistic	Perceived	alternative,	include those
complementary	Social Support	complementary	values in
alternative	- Short Blessed	therapies as part	treatment plans.
therapies.	Test	of their treatment	1
	- Brown Bag	plans for chronic	Limitations
	Medication	disease	- possible bias
	Assessment	management.	as men are
	- Medication	-AA women	excluded from
	Regimen	often incorporate	the studies.
	Complexity	faith-based	- some studies
	Index (MRCI)	interventions in	had monetary
	-Beer's	their treatment	incentives that
	Criteria,	plan	could indicate
	- Audio	- Healthcare	bias.
	recordings.	provider cultural	- results are not
		competency is	generalizable to
		essential for	most other
		successful	populations due
		medication	to limitations to
		compliance of	AA women.
		the patients.	
		- cultural	
		considerations,	
		fear of	
		medication side	
		effects, regimens,	
		and perception of	
		the cause of	
		illness affect	
		medication	
		compliance.	

7	Stormac	Systematic	Adults 18 years	Critical	-Short-Form-36	Results:	Strengths:	Level I
	q et al.	Review (SR)	and over of any	appraisal of	Health Survey	- incorporating	Extensive	
	(2020).		ethnicity and	studies with	- EuroQol	intervention	evidence was	Quality
		Aim: to identify	cultural group	HL	- Satisfaction	components that	gathered on the	Rating:
		the best	worldwide who	interventions	with Life Scale,	include cultural	effectiveness of	А
		available	are socially or		- Self-Efficacy	appropriateness,	HL	
		information on	socioeconomical		Scale	tailoring, skills	interventions	
		effective HL	ly disadvantaged		- OECD Long-	building, goal	specifically	
		interventions	in their		Term Disability	setting, active	addressed to	
		that increase	communities.		Questionnaire	discussions, and	socioeconomical	
		health-related			- Promoting	theory-based	ly disadvantaged	
		outcomes for	N=21 articles		Lifestyle	improve health-	people	
		socioeconomical			Profile	related outcomes.	worldwide.	
		ly disadvantaged			- Unmet Health	- Multi-faceted		
		people			Care Needs	interventions,	Limitations:	
		(Stormacq et al.,			indicators.	combining	- difficulty	
		2020).				information	concluding the	
						facilitation and	effectiveness of	
		Major variables:				contact with an	HL	
		health literacy				interventionist,	interventions	
		interventions,				are more	due to the large	
		health-related				effective than	number of	
		outcomes				single-modality	studies	
						interventions.	examined.	
							- the author's	
							limitation on	
							access to studies	
							- inability to	
							contact the	
							authors of two	
							eligible studies	
							with potentially	
							good data, thus,	

8	Tran et	Retrospective	Population:	Lipid	- Chi-square	- Treatment	were excluded from the review. Strength:	Level III
0	al.	cross-sectional	adults with HLD	monitoring	test and	- Iteatment intensification	Significant	Level III
	(2022).	study.	and prescribed	and	odds ratios on	increased when	representation of	Quality
	· · /	,	≥1 LDL-C	subsequent	treatment	lipid levels were	the AA	Rating:
		Aim: To	lowering	HLD	intensification	monitored	population (50%	В
		determine the	therapy and with	treatment	and lipid values	closely compared	of participants),	
		number of	more than one	intensification	- Lipid	to no monitoring.	mostly AA	
		patients that	outpatient	(higher statin	monitoring was		females.	
		completed	encounter	dose or	defined as at	- Lipid		
		appropriate lipid	during 2018 and	addition of	least one lipid	monitoring	Limitations: not	
		monitoring at an	2019 (Tran et	another lipid-	panel during	occurred less	generalizable	
		urban academic	al., 2022)	lowering	the 12-month	frequently in	due to subjects	
		medical center	Catting A.	drug) in the	follow-up	black or African	recruited from	
		and investigate if an association	Setting: An urban academic	12-month	period. - Statin use and	American individuals (odds	the medical center's	
		exists between	medical center	study period.	intensity were	ratio 0.78, 95%	outpatient	
		lipid monitoring	located in		classified	confidence	clinics only.	
		and treatment	Richmond,		according to	interval [CI])	ennies only.	
		intensification.	Virginia		current	0.69 to 0.89)	-possible biased	
		memoriourioni	(inglinia		practice.	0.09 to 0.099	interpretation of	
		Major variables:	N=12, 332		- "Treatment		sample	
		lipid	,		intensification		demographics	
		monitoring,			was defined as		due to the	
		treatment			a dose increase,		exclusion of	
		intensification,			change to a		6,520 subjects	
		statin use			higher intensity		who did not	
					statin, or		meet the criteria	
					addition of a		for the study.	
					new lipid-		- some subject	
					lowering		lab panels were	
					therapy" (Tran		incomplete, but	

					et al., 2022,		the authors were	
					p.492).		unsure if it was	
					p. 172).		due to non-	
							adherence or	
							incomplete lab	
							orders.	
							- additional	
							factors, such as	
							education,	
							income, and	
							marital status,	
							were	
							unavailable but	
							may have	
							provided more	
							insight for the	
0	T 7 1	o :			A 1		study.	T 1 TT
9	Vaugha	Quasi-	Population &	The Dittelsensels	- Automated	Four classes of	Strengths:	Level II
	n et al. (2018)	experimental	setting - two low-income,	Pittsburgh Hill/	Self- Administered	attitudes were identified that	- the use of	Quality
	(2018)	Aim- to identify	predominantly	HIII/ Homewood	24-hour recall	can inform	accelerometers, the gold-	Quality Rating:
		profiles of	AA	Research on	for food	efforts to tailor	standard method	B
		attitudes and	neighborhoods	Eating,	- self-reported	individual-level	of measuring	D
		barriers to diet	in the same city	Shopping, and	minutes of	interventions for	PA	
		and PA that	in the same enty	Health	walking	diet and PA for	- Examining	
		distinguish	N=982	(PHRESH)	measured by	people at high	attitudes and	
		subgroups of	10 902	and PHRESH	the	risk of chronic	barriers to a	
		individuals and		Plus	International	diseases.	healthy diet and	
		determine		questionnaires	Physical	These classes	PA in an	
		whether these		*	Activity	are:	underserved,	
		profiles			Questionnaire	(a) a moderate	understudied	
		demonstrate			- average daily	diet and negative	population.	
		associations			minutes of	exercise attitudes		

		with diet and PA (Vaughan et al., 2018)			moderate to vigorous PA (MVPA) using data collected	(b) few barriers and benefits of a healthy diet and exercise	Limitations: - low generalizability of findings to	
		Major variables IV-a latent profile analysis of attitudes and barriers to diet and PA DV1- Social cognitive constructs, including (self- efficacy, social norms, and internal and external barriers to diet and exercise) DV2- PA and diet			with a tri-axial accelerometer worn by participants for seven consecutive days.	(c) moderate overall attitudes (d) positive overall attitudes.	other populations as most participants were single, AA women without children. - a lack of correspondence during a 2-year gap between assessments of diet and PA and the use of self- report measures of diet and walking, resulting in a high risk of social	
1 0	William s et al. (2021)	Cohort study Aim: Evaluate the impact of a nutrition intervention in AAs on risk factors and	Population- African American (AA) adults aged 18 and over. Setting-an urban,	5-week non- dairy vegetarian nutrition intervention.	 ACC/AHA atherosclerotic cardiovascular disease (ASCVD) risk scores A self- reported 	Significant improvement in cardio-metabolic risk factors, particularly marked reductions in serum insulin	desirability bias. Strengths: - A majority female sample (83%), who are generally under- represented in cardiovascular research studies.	Level IV Quality Rating: B

biomarkers predominantly associated with AA community collect 0.000, Southern dietary participants' hemoglobin AL pattern among 0.000, weight identified as solution, low-calorie, zero collect 0.000, weight identified as ubstantially calorie, zero collect 0.000, weight ifstyle and BMI (-10.2 substantially variables. baseline dietary bis, 33 to 31 increasing cholesterol, non-dairy vegetarian 0.000, CVD up to 56% trimethylamine-diet 1. DV1 - serum 0.000, CVD up to 56% trimethylamine-diet 1. DV2 - 10-year ASCVD risk 0.000, CVD up to 56% dense low- interventions to density include fewer lipoprotein fat-rich, sugar-cholesterol sweetened (LDL) (24.2 to drinks and 19.1 mg/dL, -12%, p = 0.0000, tall 0.12, -14%, p = 0.0000, tall 0.12, -12%, p = 0.0000, tall 0.14, -12%, p = 0.0000, tall 0.12, -12\%, p = 0.0000, tall 0.12, -12\%, p = 0.0000, tall 0.12, -12\%,					
CVD.church.participants'hemoglobin Alcpattern amongMajor variables: - IV- a low-N=44baseline dictary patterns and patterns and ifestyle $(6.2\% to 6.0\%, p$ AAs, wasaodium, low- calorie, zero cholesterol, non- dairy vegetarian diet- DV1- serum= 0.000), weight identified asincreasing kg/m2, p =baseline difestyle wariables.0.000, kg/m2, p =healt risks for- DV1- serum metabolic2.9 µmol/L, biomarkersstroke. This will- DV2- 10-year ASCVD risk- 43%, p =help tailor- DV2- 10-year ASCVD risk- 0.001), small dietary dense low- interventions to density lipoprotein fat-rich, sugar- cholesterol mg/dL, -14%, p =Limitations: (121 to 104- 21%, p = 0.000), total cholesterol- Limited mg/dL, -14%, pLimitations: cholesterol mg/dL, -12%, p- 0.000), total cholesterol (TC) garticipants- Short study duration (5		1 1	1	× • 1	-
Major variables: - IV- a low-N=44baseline dietary patterns and lifestyle $(6.2\%$ to 6.0% , p 0.000 , weight and BMI (-10.2 substantially ustatially icatoric, zero cholesterol, non- dairy vegetarian $and BMI (-10.2)(To non-dairy vegetarianbaseline dietaryicatoric, zerovariables.baseline dietaryicatoric, zero(D000), weightand BMI (-10.2substantiallyicatoric, zeroCVD up to 56%othight risk for0.000), CVD up to 56%othight risk ofstroke. This willdiet- DV1- serummetabolicbiomarkersN-oxide (5.1 to)higher risk ofstroke. This willdietarydense low-dietarydense low-dietarydense low-dietarydense low-dietarydense low-dietarydense low-dietarydense low-densityinclude fewerlipoprotein19.1 mg/dL, processed foods.-21\%, p =0.000, tal0.000, tal0.012 to 1040.000, talmg/dL, -12\%, p0.000, talonly 75% ofcholesterol TCD participants(190 to 168mured themg/dL, -12\%, p0.000, tal0.000, tal0.0000, tal0.0000, tal0.0000, tal0.000$		2		<i>,,</i>	5
-IV-a low- N=44 sodium, low- calorie, zero cholesterol, non- dairy vegetarian diet $-DV1-$ serum metabolic biomarkers $-DV2- 10-$ year ASCVD risk $= 0.000$, weight and BMI (-10.2 substantially increasing kg/m2, p = health risks for 0.000), CVD up to 56% trimethylamine- higher risk of 2.9 µmol/L, stroke. This will dietary dense low- interventions to density include fewer lipoprotein fat-rich, sugar- cholesterol (LDL) (24.2 to drinks and 19.1 mg/dL, processed foods. $-21%$, p= 0.000), tcal cholesterol (TC) participants (121 to 104 cholesterol (TC) participants (121 to 168 mg/dL, -12%, p = 0.000), cholesterol (120 to 1		church.		0	1 0
sodium, low- calorie, zero cholesterol, non- dairy vegetarian diet - DV1- serum metabolicinfestyle variables.and $BM1(-10.2)$ usystantially solution increasing kg/m2, p = health risks for 0.000), CVD up to 56% trimethylamine- and a 30%- DV1- serum metabolic biomarkersN-oxide (5.1 to upmol/L, stroke. This will outpet and a 30%- DV2- 10-year ASCVD risk0.001, small dietary dense low- interventions to density include fewer lipoprotein (LDL) (24.2 to 0.000), LDL 0.000, LDL Limitations: (121 to 104 $-$ Limited mg/dL, -12% , p = $0.0000,$ total outpet of the mg/dL, -12% , p follow-up as $= 0.0000,$ total outpet of the mg/dL, -12% , psurveys. $= 0.0000,$ cholesterol (TCD) cholesterol (TCD) participants returned the mg/dL, -12% , psurveys. $= 0.0000,$ cholesterol (TCD) participantsweeks	Major variables:		baseline dietary	(6.2% to 6.0%, p	AAs, was
calorie, zero cholesterol, non- dairy vegetarianvariables.lbs, 33 to 31 (kg/m2, p = bealth risks for bealth risks for 0.000),creasing (kg/m2, p = bealth risks for 0.000),diet - DV1- serum metabolic biomarkers - DV2- 10-yearN-oxide (5.1 to $-3\%, p =$ belp tailor dietary dense low- interventions to idensity there were lipoprotein fat-rich, sugar- scholesterol (LDL) (24.2 to $-21\%, p =$ $0.000), total0.000, totallbs, 33 to 31increasingkg/m2, p =health risks for0.000, 0$	- IV- a low-	N=44	patterns and	= 0.000), weight	identified as
cholesterol, non- dairy vegetariankg/m2, p = 0.000),health risks for 0.000),diet0.000),CVD up to 56%- DV1- serumN-oxide (5.1 to bigher risk ofmetabolic2.9 μ mol/L, stroke. This willbiomarkers-43%, p =- DV2- 10-year0.001), smallASCVD riskdietarydense low- lipoproteininterventions to fat-rich, sugar- cholesterolsweetened(LDL) (24.2 to dirinks and 19.1 mg/dL, processed foods. -21%, p =0.000), LDLLimitations: (121 to 104)(121 to 104)-Limited mg/dL, -14%, pmg/dL, -14%, pfollow-up as of cholesterol (TCD) participantsmg/dL, -12%, psurveys. surveys. = 0.000), totalmg/dL, -12%, psurveys. surveys. = 0.000).mg/dL, -12%, psurveys. surveys. = 0.000).mg/dL, -12%, psurveys. surveys. = 0.000).mg/dL, -12%, psurveys. surveys. = 0.000).Kecommendationweeks)	sodium, low-		lifestyle	and BMI (-10.2	substantially
dairy vegetarian 0.000 ,CVD up to 56%diettrimethylamine-and a 30%- DV1- serumN-oxide (5.1 tohigher risk ofmetabolic2.9 µmol/L,stroke. This willbiomarkers-43%, p =help tailor- DV2- 10-year0.001), smalldietaryASCVD riskdense low-interventions todensityinclude fewerlipoproteinfat-rich, sugar-cholesterolsweetened(LDL) (24.2 todrinks and19.1 mg/dL,p =0.000), tDLLimitations:(121 to 104- Limitedmg/dL, -14%, p =0.000, totalonly 75% ofcholesterol (TC)p articipants(190 to 168mg/dL, -12%, p =0.000).o.000).surveys.= 0.000) Short studyduration (5Recommendationweeks)	calorie, zero		variables.	lbs, 33 to 31	increasing
diet trimethylamine- and a 30% - DV1- serum N-oxide (5.1 to higher risk of metabolic 2.9 µmol/L, stroke. This will biomarkers - DV2-10-year 0.001), small dietary ASCVD risk dense low- interventions to density include fewer lipoprotein fat-rich, sugar- cholesterol sweetened (LDL) (24.2 to drinks and 19.1 mg/dL, processed foods. -21%, p = 0.000, LDL Limitations: (121 to 104 - Limited mg/dL, -14%, p follow-up as = 0.000, total only 75% of cholesterol (TC) participants (190 to 168 returned the mg/dL, -12%, p = 0.000). $-$ Short study duration (5	cholesterol, non-			kg/m2, p =	health risks for
$\begin{array}{llllllllllllllllllllllllllllllllllll$	dairy vegetarian			0.000),	CVD up to 56%
metabolic $2.9 \ \mu m J/L$,stroke. This willbiomarkers -43% , p =help tailor $-DV2-10$ -year 0.001), smalldietaryASCVD riskdense low-interventions todensityinclude fewerlipoproteinfat-rich, sugar-cholesterolsweetened(LDL) (24.2 todrinks and19.1 mg/dL,processed foods. -21% , p = 0.000 , LDLLimitations:(121 to 104) $-Limited$ mg/dL, -14% , p mg/dL , -12% , follow-up as $= 0.000$, totalonly 75% ofcholesterol (TC)participants $(190 to 168)$ returned the mg/dL , -12% , psurveys. $= 0.000$. $-$ Short study $duration (5)$ Recommendationweeks) $weeks$	diet			trimethylamine-	and a 30%
biomarkers -DV2-10-year ASCVD risk dietary ASCVD risk dietary	- DV1- serum			N-oxide (5.1 to	higher risk of
- DV2- 10-year ASCVD risk 0.001 , small dietary dense low- interventions to density include fewer lipoprotein fat-rich, sugar- cholesterol sweetened (LDL) (24.2 to drinks and 19.1 mg/dL, processed foods. -21%, p = 0.000), LDL Limitations: (121 to 104 - Limited mg/dL, -14%, p follow-up as = 0.000), total only 75% of cholesterol (TC) participants (190 to 168 returned the mg/dL, -12%, p surveys. = 0.000) Short study duration (5 Recommendation weeks)	metabolic			2.9 μmol/L,	stroke. This will
ASCVD risk dense low- interventions to density include fewer lipoprotein fat-rich, sugar- cholesterol sweetened (LDL) (24.2 to drinks and 19.1 mg/dL, processed foods. -21%, p = 0.000), LDL Limitations: (121 to 104 - Limited mg/dL, -14% , p follow-up as = 0.000), total only 75% of cholesterol (TC) participants (190 to 168 returned the mg/dL, -12% , p surveys. = 0.000), $-$ Short study duration (5 Recommendation weeks)	biomarkers			-43%, p =	help tailor
densityinclude fewerlipoproteinfat-rich, sugar-cholesterolsweetened(LDL) (24.2 todrinks and19.1 mg/dL,processed foods. -21% , p = -21% , p =0.000), LDLLimitations:(121 to 104- Limitedmg/dL, -14\%, pfollow-up as= 0.000), totalonly 75% ofcholesterol (TC)participants(190 to 168returned themg/dL, -12%, psurveys.= 0.000) Short studyduration (5Recommendationweeks)	- DV2- 10-year			0.001), small	dietary
lipoproteinfat-rich, sugar- sweetenedcholesterolsweetened(LDL) (24.2 todrinks and19.1 mg/dL,processed foods. -21% , p =0.000), LDLLimitations:(121 to 104- Limitedmg/dL, -14%, pfollow-up as= 0.000), totalonly 75% ofcholesterol (TC)participants(190 to 168returned themg/dL, -12%, psurveys.= 0.000) Short study duration (5Recommendationweeks)	ASCVD risk			dense low-	interventions to
cholesterol sweetened (LDL) (24.2 to drinks and 19.1 mg/dL, processed foods. -21%, p = 0.000), LDL Limitations: (121 to 104 - Limited mg/dL, -14\%, p follow-up as = 0.000), total only 75% of cholesterol (TC) participants (190 to 168 returned the mg/dL, -12\%, p surveys. = 0.000) Short study duration (5 Recommendation weeks)				density	include fewer
(LDL) (24.2 to 19.1 mg/dL, $=$ drinks and processed foods. -21% , $p =$ 0.000), LDLLimitations: (121 to 104) $=$ Limited mg/dL, -14% , pfollow-up as follow-up as $= 0.000$), total $= 0.000$), total $= 0.000$), total $= 0.000$, $=$ Short study duration (5) Recommendation $=$ Weeks)				lipoprotein	fat-rich, sugar-
19.1 mg/dL, $p =$ processed foods. $-21\%, p =$ 0.000), LDLLimitations: $(121 \text{ to } 104$ - Limited $mg/dL, -14\%, p$ follow-up as $= 0.000$), totalonly 75% ofcholesterol (TC)participants $(190 \text{ to } 168$ returned the $mg/dL, -12\%, p$ surveys. $= 0.000$) Short studyduration (5Recommendationweeks)				cholesterol	sweetened
$-21\%, p =$ $-21\%, p =$ $0.000), LDL \qquad \text{Limitations:}$ $(121 \text{ to } 104 \qquad - \text{Limited}$ $mg/dL, -14\%, p \qquad \text{follow-up as}$ $= 0.000), \text{ total} \qquad \text{only } 75\% \text{ of}$ $\text{cholesterol (TC)} \qquad \text{participants}$ $(190 \text{ to } 168 \qquad \text{returned the}$ $mg/dL, -12\%, p \qquad \text{surveys.}$ $= 0.000). \qquad - \text{Short study}$ $duration (5)$ Recommendation $\text{weeks})$				(LDL) (24.2 to	drinks and
$\begin{array}{llllllllllllllllllllllllllllllllllll$				19.1 mg/dL,	processed foods.
$(121 \text{ to } 104 \ \text{mg/dL}, -14\%, \text{p} \ \text{follow-up as}$ $= 0.000$), totalonly 75% of $= 0.000$), totalonly 75% of $(190 \text{ to } 168 \ \text{mg/dL}, -12\%, \text{p} \ \text{surveys.}$ $= 0.000$) Short study $= 0.000$) Short study $duration (5 \ \text{Recommendation} \ \text{weeks})$				−21%, p =	
$mg/dL, -14\%, p follow-up as \\ = 0.000), total only 75\% \text{ of} \\ cholesterol (TC) participants \\ (190 to 168 returned the \\ mg/dL, -12\%, p surveys. \\ = 0.000). - Short study \\ duration (5 \\ Recommendation weeks)$				0.000), LDL	Limitations:
= 0.000), total only 75% ofcholesterol (TC) participants(190 to 168 returned themg/dL, -12%, p surveys.= 0.000). - Short studyduration (5Recommendation weeks)				(121 to 104	- Limited
cholesterol (TC) $(190 to 168)$ $mg/dL, -12\%, p$ participants returned the surveys. $= 0.000$) Short study duration (5Recommendationweeks)				mg/dL, -14%, p	follow-up as
$\begin{array}{ll} (190 \text{ to } 168 & \text{returned the} \\ mg/dL, -12\%, p & \text{surveys.} \\ = 0.000). & - \text{Short study} \\ & \text{duration (5)} \\ \text{Recommendation} & \text{weeks)} \end{array}$				= 0.000), total	only 75% of
mg/dL, -12%, p surveys. = 0.000) Short study duration (5 Recommendation weeks)				cholesterol (TC)	participants
= 0.000) Short study duration (5 Recommendation weeks)				(190 to 168	returned the
duration (5 Recommendation weeks)				mg/dL, −12%, p	surveys.
Recommendation weeks)				= 0.000).	- Short study
					duration (5
: Adherence to insufficient to				Recommendation	weeks)
				: Adherence to	insufficient to
this vegetarian address the				this vegetarian	address the

diet low in long-term reduction in risk sodium, cholesterol, or accurately refined measure carbohydrates, accumulated saturated fats, health events. and sweetened beverages "will - Lack of a dramatically control group reduce and does not account possibly for non-dietary eradicate the factors, such as improved racial disparity in ASCVD events medication and mortality adherence, that rates if 19% of may have the 21% increase affected the is eliminated by results but were this lifestyle not reported by change" the participants. Williams et al. (2021, p. 2). Underestimation in the 10-year risk score due to the removal of 8 subjects from the ASCVD pooled cohort equation/ calculation due to successfully lowered lipid

	levels below
	130.
	- Most
	participants
	were female
	(83%). Thus,
	males were
	under-
	represented
	though they
	have higher CV
	mortality rates
	than women.
<i>Note</i> : This table summarizes the evidence supporting the intervention for the PICOT. AA= A	frican American, ACC= American
College of Cardiology, AHA= American Heart Association, ASCVD= atherosclerotic cardio	ovascular disease, A1C= average blood
sugar, BMI= body mass index, BP= blood pressure, CBPR= community-based participatory	research, CI= confidence interval, CAT=
Complimentary alternative therapies, CVD= cardiovascular disease, dL= deciliter, DWPC	= Diabetes Wellness and Prevention
Coalition, DG= dietitian group, DV= dependent variable, FV= fruit and vegetable, GP=gener	al practitioner, HBCU= Historically
Black Colleges and Universities, HC=health coaching, HL= health literacy, HDL= high-den	nsity lipoprotein, HLD= hyperlipidemia,

Complimentary alternative therapies, CVD= cardiovascular disease, dL= deciliter, DWPC= Diabetes Wellness and Prevention Coalition, DG= dietitian group, DV= dependent variable, FV= fruit and vegetable, GP=general practitioner, **HBCU= Historically Black Colleges and Universities,** HC=health coaching, HL= health literacy, HDL= high-density lipoprotein, **HLD= hyperlipidemia**, IPAQ= International Physical Activity (PA) Questionnaire, IV= independent variable, lbs= pounds, LDL= low-density lipoprotein, mg= milligram, **n= number**, N= sample size, OECD= Organization **for Economic** Cooperation **and Development**, PA= physical activity, PG= physician group, p= probability, **RCT= randomized control trial**, SDSCA= Summary of Diabetes Self-Care Activities Questionnaire, TC= total cholesterol, TM= text messaging, umol= micromole.

Appendix C

Organization Approval Letter



Aicon Jamily Clinic

16261 FM 529 Rd, STE. A. Houston TX 77095 Tel: 282-550-5388; Fax: 281-550-5325

The University of Texas at Arlington,

701 S. Nedderman Drive

Arlington, TX 76019

Good day Sir/Madam,

To Whom It May Concern


This is to confirm with the University of Texas at Arlington School of Nursing that DNP student Loretta Bennam will be conducting her clinical/DNP Capstone project at Aicon Family Clinic.

Sincerely,

Kindness Chukwukere FNP-BC Aicon Family Clinic 16261 FM 529 Rd, Ste A, Houston Texas 77095 PH: 281-550-5388

Appendix D

Johns Hopkins Nursing Evidence-Based Practice (JHNEBP) Model



©The Johns Hopkins Hospital/The Johns Hopkins University

Appendix E

Project Invitation Script for Nurse Practitioners

"Good morning, Mr./Mrs. X,

The clinic is conducting a project to improve the heart health of African American patients in our community. The project focuses on treating high cholesterol, promoting healthy diets, and increasing physical activity. To qualify as a participant, you must meet specific criteria. It uses evidence-based guidelines, and your participation comes at no extra cost to you. Will you be interested in hearing more about the project?"

Appendix F DNP Project Team Education PowerPoint



Improving Heart Health in African American Adults Using a Cardiovascular Disease Bundle

DNP Project Team Education Loretta Bennam College of Nursing and Health Innovation, The University of Texas Arlington 6/10/2023

Heart Disease

- Heart disease is a significant cause of mortality in the United States of America (USA) and worldwide.
- 17.5 million people die annually from cardiovascular disease (CVD) worldwide (WHO, 2022)
- CVD kills 695,000 people annually in the USA
- one person dies every five seconds from heart disease in the USA (CDC, 2020).
- The leading cause of death in Texas in 2017 was heart disease (CDC, 2018)

Heart Disease in African Americans

Black, non-Hispanic African Americans (AAs) have the highest percentage of deaths per race due to heart disease (CDC, 2022).

less likely to be treated with statin medications than Caucasians (71% vs. 75%, p=0.02) (Nanna et al., 2018)

20% less likely to engage in active physical activity than non-Hispanic Whites in 2018;

1.3 times more likely to be obese than Caucasians (US Department of Health and Human Services, 2019)

AAs have the highest death rate in Houston, Texas, from coronary artery disease (Houston State of Health, 2023)

Slide D3

Risk Factors for Heart Disease

- Elevated Low-density Lipoprotein (LDL) Or "Bad Cholesterol"
- Obesity
- Physical Inactivity
- Unhealthy Diet,
- Diabetes Mellitus,
- Excessive Alcohol Use,
- High Blood Pressure, And
- Smoking
- (CDC, 2020).

For the project, we will focus on three risk factors

- Obesity,
- High LDL Cholesterol
- Physical Inactivity

The DNP Capstone Project

The project is implementing a CVD bundle to decrease heart disease in African American adults

3 main sections:

- · assessing cholesterol medication adherence
- · identifying profiles of attitudes and barriers to physical activity
- patient education (pamphlet will be provided)

Goal: Improve heart health by promoting cholesterol medication adherence, weight reduction, and improving physical activity.

Subjects:

Data

Collection

Non-Hispanic African American adults

• BMI of 30 kg/m² and over (obese)

· LDL cholesterol levels above 100 mg/dl

• Weight measurements

• Medication Adherence Report Scale (MARS-5) questionnaire

- assesses the patient's medication adherence or compliance

• Rapid Assessment of Physical Activity (RAPA) questionnaire

- to measure physical activity by the patient's report


• Measure LDL cholesterol levels at the end of the project

Slide D6



- Weight measurements should be done on a standing scale
- Zero the scale before obtaining the weight
- Have the subject remove shoes and any heavy clothing like jackets or sweaters
- Record the weight to one decimal fraction, e.g., 200.2 lbs

(CDC, 2021)



Slide D7

Record Keeping

Accurate weight measurements should be recorded in the patient's chart

Completed consent forms and questionnaires must be scanned into patient charts in the electronic health record (EHR)

All forms must have subject MRN number as patient identifier

LDL cholesterol levels will be drawn at the end of the 10-week project

Sign-in Sheet with subject MRN numbers

Project Invitation Script

"Good morning, Mr./Mrs. X,

The clinic is conducting a project to improve the heart health of African American patients in our community. The project focuses on treating high cholesterol, promoting healthy diets, and increasing physical activity. To qualify as a participant, you must meet specific criteria. It uses evidence-based guidelines, and your participation comes at no extra cost to you. Will you be interested in hearing more about the project?" Slide D9

Forms

When the subject agrees to participate, ensure they receive these forms:

- · Sign-in Sheet
- · Demographics question sheet
- The project consent form
- MARS-5 questionnaire
- RAPA questionnaire
- Patient education pamphlet

The project lead and NPs will give more details and complete data collection with the patient.

References

Centers for Disease Control and Prevention. (2018). Stats of the state of Texas. National centers

for health statistics. https://www.cdc.gov/nchs/pressroom/states/texas/texas.htm

Centers for Disease Control and Prevention. (2020). Heart Disease and stroke.

https://www.cdc.gov/chronicdisease/resources/publications/factsheets/heart-disease-

stroke.htm#:~:text=Leading%20risk%20factors%20for%20heart

Centers for Disease Control and Prevention. (2021). Measuring children's height and weight accurately at home.

https://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/measuring_children.html/#weight

Centers for Disease Control and Prevention. (2022). Heart disease facts. https://www.cdc.gov/heartdisease/facts.htm

Houston State of Health. (2023). Disparities dashboard.

https://www.houstonstateofhealth.com/indicators/index/dashboard?alias=disparities

References

Nanna, M. G., Navar, A. M., Zakroysky, P., Xiang, Q., Goldberg, A. C., Robinson, J., Roger, V. L., Virani, S. S., Wilson, P. W. F., Elassal, J., Lee, L. V., Wang, T. Y., & Peterson, E. D. (2018). Association of patient perceptions of cardiovascular risk and beliefs on statin drugs with racial differences in statin use. *JAMA Cardiology*, 3(8), 739–748. https://doi.org/10.1001/jamacardio.2018.1511

US Department of Health and Human Services. (2019). *Obesity - the office of minority health*. Hhs.gov. https://minorityhealth.hhs.gov/omh/browse.aspx?lvl=4&lvlid=25

World Health Organization. (2022). Cardiovascular diseases.

https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1

Appendix G

GANNT Chart for DNP Project Weeks 1-8

In	Improving CV Health in African American Adults Using a CVD Bundle												
UT	UT Arlington SON DNP Program												
	Project Start Date Project Lead	8/28/2023 (Monday) Loretta Bennam	Display We	ek	1-Jan	Week 1 28 Aug 2023 28 29 30 31 1 2 3	Week 2 4 Sep 2023 4 5 6 7 8 9 1	Week 3 11 Sep 2023 0 11 12 13 14 15 16 17	Week 4 18 Sep 2023 18 19 20 21 22 23 24	Week 5 25 Sep 2023 25 26 27 28 29 30 1	Week 6 2 Oct 2023 2 3 4 5 6 7 8	Week 7 9 Oct 2023 9 10 11 12 13 14 15	Week 8 16 Oct 2023 16 17 18 19 20 21 22
WBS	TASK CATEGORY				WORK DAYS			s M T W T F S S					
1		Loretta											
1.1	Staff Training	Mon 8/28/23	Tue 8/29/23	2	2								
1.2	Recruiting Subjects	Wed 8/30/23	Wed 9/20/23	21	16								
1.3	Implementing Intervention	Wed 8/30/23	Wed 9/20/23	21	16								
1.4	Provide paper copies of forms	Mon 8/28/23	Wed 9/20/23	23	18								
1.4.1	Quality check of completed forms	Wed 8/30/23	Fri 11/03/23	21	48								
1.4.2	Organize data on Excel spreadsheet for analysis	Mon 9/25/23	Fri 10/13/23	18	15								
1.5	Initiate two-week follow up calls	Mon 9/25/23	Fri 10/13/23	18	15								
1.6	Post-intervention visits & data collection	Mon 10/02/23	Fri 11/03/23	18	25								
2													
2.1													
2.2													
2.3													
2.4													
2.5													
3													

Appendix H

MARS-5 Questionnaire

MARS_5

QUESTIONS ABOUT USING YOUR MEDICINES

- Many people find a way of using their medicines which suits them.
- This may differ from the instructions on the label or from what their doctor has said.
- We would like to ask you a few questions about how you use your medicines

Here are some ways in which people have said that they use their medicines

For each of the statements, please tick the box which best applies to you

	Your own way of using your medicines	Alwaya	Often	Sometimes	Rarely	Never
MH	I forget to take them					
M2	I alter the dose					
MB	I stop taking them for a while					
MM	I decide to miss out a dose					
MS	I take less than instructed					

MARI_52018 (1) (4) (2) Medication Adherence Report Scale (MARS_5) © Professor Rob Home

Appendix I

Rapid Assessment of Physical Activity (RAPA) Questionnaire

Rapid Assessment of Physical Activity

Physical Activities are activities where you move and increase your heart rate above its resting rate, whether you do them for pleasure, work, or transportation.

The following questions ask about the amount and intensity of physical activity you usually do. The intensity of the activity is related to the amount of energy you use to do these activities.

Light activities • your heart beats slightly faster than normal • you can talk and sing	Walking Leisurely	Stretching	Vacuuming or Light Yard Work
 Moderate activities your heart beats faster than normal you can talk but not sing 	Fast Walking	olabo	Strength Training Swimming Gently
Vigorous activities • your heart rate increases a lot • you can't talk or your talking is broken up by large breaths	Stair Machine	Jogging or Running	Tennis, Racquetball, Pickleball or Badminton

Examples of physical activity intensity levels:

-		Does this accurately describe you?
	I rarely or never do any physical activities.	Yes No
	I do some light or moderate physical activities, but not every week.	Yes No
	I do some light physical activity every week.	Yes No
	I do moderate physical activities every week, but less than 30 minutes a day or 5 days a week.	Yes No
	I do vigorou s physical activities every week, but less than 20 minutes a day or 3 days a week.	Yes No
	I do 30 minutes or more a day of moderate physical activities, 5 or more days a week.	Yes No
	I do 20 minutes or more a day of vigorous physical activities, 3 or more days a week.	Yes No
1	I do activities to increase muscle strength , such as lifting weights or calisthenics, once a week or more.	Yes No
2	I do activities to improve flexibility , such as stretching or yoga, once a week or more.	Yes No
	1	I do some light or moderate physical activities, but not every week. I do some light physical activity every week. I do moderate physical activities every week, but less than 30 minutes a day or 5 days a week. I do vigorous physical activities every week, but less than 20 minutes a day or 3 days a week. I do 30 minutes or more a day of moderate physical activities, 5 or more days a week. I do 20 minutes or more a day of vigorous physical activities, 3 or more days a week.

How physically active are you? (Check one answer on each line)

ID # _____ Today's Date _____

Appendix J

Heart Disease Knowledge Survey

Question	Poor	Fair	Good	Very Good	Excellent
1. How would you rate your knowledge about high cholesterol?					
2. How would you rate your knowledge about physical activity and exercise?					
3. How would you rate your knowledge about the risk factors for heart disease?					
4. How would you rate your knowledge about eating healthy to prevent heart disease?					

Rating Scale (score range 4-20)

- 1 = Poor
- 2= Fair
- 3=Good
- 4= Very good
- 5= Excellent

Appendix K

Heart Disease Patient Education Pamphlet

Increase Your Physical Activity

-AHA recommends 150 minutes per week of moderate-intensity aerobic activity or 75 minutes of vigorous aerobic activity weekly or a combination of both -Take brisk walks in your neighborhood park -Jog or walk on the treadmill three days a week as tolerated or for 30 minutes per session -Park further from the entrance at work to include more physical activity -Use stairs instead of the elevator as tolerated -Aim to be more physically active than you currently are (AHA, 2018)

Obesity Defined as BMI greater than 30 kg/m2 Eating healthy, exercising, and avoiding excess calories help prevent obesity (CDC, 2019b)

References

American Heart Association. (2018). American heart association recommendations for physical activity in adults and kids. Www.heart.org.https://www.heart.org/en/heal thy-living/fitness/fitness-basics/aha-recs-forphysical-activity-in-adults

American Heart Association. (2019). Healthy eating. Www.heart.org. https://www.heart.org/en/healthyliving/healthy-eating

Centers for Disease Control and Prevention. (2019a). About high blood cholesterol. https://www.cdc.gov/cholesterol/about.htm

Centers for Disease Control and Prevention. (2019b). Knowing your risk: High cholesterol. Centers for Disease Control and Prevention. https://www.cdc.gov/cholesterol/risk_factors. htm

National Heart Lung and Blood Institute (2021). On the move to better heart health for African Americans.

https://www.nhlbi.nih.gov/resources/movebetter-heart-health-african-americans

Reduce Your Risk for Heart Disease





Risk Factors

High cholesterol* Obesity* Physical Inactivity*

Also.....

Smoking Excessive alcohol use High blood pressure Unhealthy diet (CDC, 2019b)

Goals

- 1. Eat healthy.
- 2. Take your cholesterol medication.
- 3. Increase your physical activity.

Eating Healthy

- Choose minimally processed food or avoid them altogether
- Eat a variety of fruit and vegetables
- Have healthy protein from plant sources and seafood
- Choose whole-grain foods
- Use liquid non-tropical plant oils, e.g., olive oil
- Reduce salt intake
- Limit alcohol consumption (AHA, 2019; NHLBI, 2019)

High Cholesterol

- LDL or low-density lipoprotein is referred to as 'bad cholesterol"
- Normal values of LDL in less than 100 mg/dl
- Decreasing LDL numbers reduces the risk of heart disease.
- Taking your cholesterol medication daily or as prescribed is very important.
- Set a reminder to take your medication
 Taking medications at the same time every day improves compliance
 (CDC, 2019a)

Appendix L

Demographic Data Questionnaire

- 1. Are you African American? Yes_____ No____
- Are you of Latino origin? Yes_____ No____ (If yes, you do not qualify for this project)
- 3. Please indicate your birth gender.

 Male______ Female_____
- 4. Please indicate your highest level of education High school degree or less_____ Associate's degree____Bachelor's degree_____ Master's degree or higher
- 5. What is your marital status? Single____ Married____ Divorced or separated_____ Widowed_____
- 6. What is your employment status? Employed Unemployed

Appendix M Database Dashboard for Data Collection

Table Q1

Participant Code	Weight (lbs)		8		MARS-5 Score (Range 5-25)		RAPA-1 Score (Range 0-7)		RAPA-2 Score (Range 0-3)		
	Pre	Post	Pre	Post	Pre	Post	RAPA- 1 Pre	RAPA- 1 Post	RAPA- 2 Pre	RAPA-2 Post	
28-19-006 See Appendix Q for code	250	230	189	150	9	19	7	7	1	3	

Table Q2

MARS-5										
Participant	<mark>Q#1</mark>	<mark>Q#2</mark>	<mark>Q#3</mark>	<mark>Q#4</mark>	<mark>Q#5</mark>	<mark>Q#1</mark>	<mark>Q#2</mark>	<mark>Q#3</mark>	<mark>Q#4</mark>	<mark>Q#5</mark>
Code	<mark>Pre</mark>	<mark>Pre</mark>	<mark>Pre</mark>	<mark>Pre</mark>	<mark>Pre</mark>	<mark>Post</mark>	<mark>Post</mark>	<mark>Post</mark>	<mark>Post</mark>	<mark>Post</mark>
28-19-006	1	2	2	1	3	3	4	4	3	5
See Appendix Q										
for code										

Table Q3

RAPA Participant <mark>Q#8</mark> <mark>Q#9</mark> **Q#7** <mark>Q#1</mark> <mark>Q#2</mark> <mark>Q#3</mark> <mark>Q#4</mark> <mark>Q#5</mark> <mark>Q#6</mark> <mark>Q#7</mark> <mark>Q#1</mark> <mark>Q#2</mark> <mark>Q#3</mark> <mark>Q#4</mark> <mark>Q#5</mark> <mark>Q#6</mark> <mark>Q#8</mark> <mark>Q#9</mark> Code <mark>Pre</mark> <mark>Pre</mark> <mark>Pre</mark> <mark>Pre</mark> <mark>Pre</mark> <mark>Pre</mark> <mark>Pre</mark> <mark>Pre</mark> <mark>Pre</mark> Post <mark>Post</mark> <mark>Post</mark> <mark>Post</mark> Post **Post** Post <mark>Post</mark> <mark>Post</mark> 28-19-006 0 0 0 2 1 1 0 1 1 1 1 1 1 1 1 1 1 1 See Appendix Q for code

See Appendix N for coding explanation

A=10	B= 11
C= 12	D=13
E= 14	F= 15
G = 16	H= 17
I= 18	J= 19
K=20	L=21
M= 22	N= 23
O=24	P= 25
Q=26	R=27
S=28	T= 29
U= 30	V= 31
W= 32	X= 33
Y= 34	Z= 35

Appendix N Participant ID Master Coding System

Participant ID Code = Initial First Name – Initial Last Name—Participant number; If the first participant's name were Sarah Jones, her code would be 28-19-006.


Appendix O

Database Coding Legend for Data Analysis

File Home Insert Draw Page Layo	t Formulas Data Review View	Automate QI N	Aacros 2023	3 Help
$\begin{array}{c c} & & \\ & & \\ & & \\ Paste \\ & & \\ &$	= = = ≫ ~ eb Wrap Text = = = += += = E Merge & Center ~	General \$ ~ % 9 €		onditional Format a matting ~ Table ~
Clipboard 🕞 Font	Alignment 5	Number	r <u>s</u>	Styles
\sim \sim \sim f_{x}				
	В		С	D E
High school degree or less	= High school degree or less; 0= No high schoo	l degree or less		
Associates degree	= Associates degree; 0= No Associates degree			
Baccalaurette Degree	= Baccalaurette Degree; 0= No Baccalaurette c			
Masters degree or higher	= Masters degree or higher; 0= No masters de	<u> </u>		
		5 0		
MARS-5 Score	otal summed score of Q items (range from 5 t	o 25)		
3 Score codes	= Always			
4	= Often			
5	= Sometimes			
5	= Rarely			
7	= Never			
RAPA Scores				
RAPA 1 & 2 Score Codes Pre & Post	= Yes, 0= No			
RAPA-1 Pre & Post Total Scores	Question with the highest Yes (1) score (Range	0-7 for activity level)	
RAPA-2 Pre & Post Total Scores	he total added score of Q8 and Q9 scores (Ran	ge 0 to 3)		
Note for RAPA-2 questions	irst question is Q8; Second question is Q9			
3				
1				
5				
5				
7				
3				
Demographics LDL & Weight	MARS-5 Questionnaire RAPA Questionna	aire Legend	(+)	: •
	I		0	

Heart Disease Education Survey	Total summed score of Q items (range from 4 to 20)
Score codes	1=Poor
	2= Fair
	3= Good
	4= Very good
	5= Excellent

Appendix P



Participant LDL and Weight Pre- and Post-Data Results

Appendix Q

Permission to Use MARS-5 Questionnaire

	Permission to use the MARS-5 Questionnaire Index ×	¢	8	ß						
P	Loretta Bennam <lorybennam@gmail.com> Jul 19, 2023, 1:21 PM (17 hours ago) to r.horne ◄</lorybennam@gmail.com>	☆	¢	:						
	Good day Dr. Rob Home,									
	My name is Loretta Bennam. I am a Doctor in Nursing Practice (DNP) student at the University of Texas in Arlington. I'm am seeking permission to use The Medication Adherence Repr Scale (MARS-5) questionnaire for my capstone project to commense in August 2023. The project is on Improving Heart Health in African American Adults using a Cardiovascular Diseas Bundle. I plan to use the questionnaire to assess cholesterol medication adherence in the subjects.									
	I will greatly appreciate your approval and permission to utilize the MARS-5 questionnaire for my project.									
	Thank you in advance.									
	Sincerely,									
	Loretta Bennam.									
	Taylor, Lauren <lauren.taylor@ucl.ac.uk> € 3:58AM (to Zoe, Robert, me ▼</lauren.taylor@ucl.ac.uk>	2 hours	s ago)	☆	ب (
	Dear Loretta,									
	I hope this email finds you well. Thank you for your interest in the MARS questionnaire (please see attached, which should provide answers to your etc).	quest	ions i	ncludin	g scoring					
	We are very interested in hearing more about your findings. We ask all potential users to sign up to our standard conditions/ copyright for use of th here: https://forms.office.com/r/gYSHWRsPtd	ie MAI	RS que	estionn	aire					
	If you are happy with the conditions, please complete the form using the link. Permissions are automatic on receipt of returned form.									
	If you have any questions, please do not hesitate to ask.									
	Best wishes									
	Lauren Taylor									
	Research Fellow UCL School of Pharmacy Department of Practice and Policy Centre for Behavioural Medicine BMA House, Tavistock Square London, WC1H 9JP									
P	Loretta Bennam <lorybennam@gmail.com> to Lauren, Zoe, Robert → Dear Lauren</lorybennam@gmail.com>	<u>ب</u>	-							

Thank you for your response. I agree to the standard conditions and copyright presented. I have filled out the form as requested. I will certainly keep you updated on the findings of the study. Thank you again for your time and consideration.

Kind regards.

Loretta Bennam DNP Student University of Texas in Arlington

•••